INDIVIDUAL TEST 868
KCNA2 antibodies (IgG)
Indication
Suspected Autoimmune encephalitis or Atypical dementia.
Method
Cell-based assay (CBA), Indirect immunofluorescence(IIF). The method is not yet validated for clinical diagnostic use.
Reference interval
Serum: <1:10 negative
CSF: negative
Result
Results are reported as negative or positive. A positive result is followed by a titer (serum).
Interpretation
Autoantibodies against the potassium voltage-gated channel subfamily A 2 subunit (KCNA2), have been found in patients suffering from cognitive impairment, memory disturbance, and neuropsychiatric symptoms. Epileptic seizures, gait disorder, and ataxia have also been described.
References
Arlt FA et al. Brain Behav Immun. 2024. KCNA2 IgG autoimmunity in neuropsychiatric diseases. PMID: 38309639.
Timäus C et al. Brain Sci. 2021. KCNA2 Autoimmunity in Progressive Cognitive Impairment: Case Series and Literature Review. PMID: 33445475
Can't find what you're looking for? We are here to help
ENSKILD ANALYS 868
KCNA2-antikroppar (IgG)
Indikation
Misstanke om autoimmun encefalit eller atypisk demens.
Metod
Cell-based assay (CBA), Indirekt immunofluorescens (IIF) Metoden är ännu inte validerad för klinisk diagnostik.
Referensintervall
Serum: <1:10 negativt
Likvor: negativt
Resultat
Resultat anges som negativt eller positivt. Positivt resultat titreras (serum).
Tolkning
Antikroppar mot kaliumkanalens subenhet A 2 (KCNA2) har rapporterats förekomma vid kognitiv påverkan med minnesrubbning och neuropsykiatriska symptom. Även fall med epilepsi, gångstörning och ataxi har rapporterats.
Förekomst av antikroppar mot KCNA2 i likvor är starkare associerat med kognitiv påverkan än seropositivitet.
Referenser
Arlt FA et al. Brain Behav Immun. 2024. KCNA2 IgG autoimmunity in neuropsychiatric diseases. PMID: 38309639.
Timäus C et al. Brain Sci. 2021. KCNA2 Autoimmunity in Progressive Cognitive Impairment: Case Series and Literature Review. PMID: 33445475